Single-Use Bioreactors: Reshaping Bio-pharmaceutical Manufacturing, USD 10.0 Billion by 2028

The single use bioreactors market is on a trajectory of substantial growth, with a projected value of USD 10.0 billion by 2028 and a remarkable compound annual growth rate (CAGR) of 19.0% during the forecast period spanning from 2023 to 2028. This upward trend is propelled by various factors, prominently including the increasing adoption of single-use bioreactors among startups and small to medium-sized enterprises (SMEs). These innovative bioreactors offer advantages such as lower operational complexity in comparison to conventional stainless-steel bioreactors, reduced energy and water consumption, and significant technological advancements.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=44374840

One of the key drivers behind this market growth is the expanding size of the biologics and biosimilars market. As the demand for these products continues to surge, the need for efficient and cost-effective manufacturing processes becomes paramount, thereby fostering a greater adoption of single-use bioreactors.

In-depth research indicates that the monoclonal antibodies (mAbs) segment occupies the largest share of the molecule type segment in the single-use bioreactors market as of 2022. This prominence can be attributed to the escalating demand for mAbs across various therapeutic applications, coupled with the benefits offered by single-use bioreactors, including reduced investment costs and time-intensive changeover procedures.

Regarding cell type, the mammalian cells segment is projected to experience the most rapid growth in the single-use bioreactors market. The increasing adoption of mammalian cells stems from their capacity for post-translational modifications and the assembly of human protein-like molecular structures, both of which are integral in biopharmaceutical production.

The Asia Pacific region emerges as the fastest-growing geographic segment in the single-use bioreactors market as of 2022. Factors such as the thriving biopharmaceutical industry, augmented investments by pharmaceutical and biotechnology companies, and the presence of contract research organizations (CROs) and contract manufacturing organizations (CMOs) collectively contribute to the market's expansion in this region.

Leading players in the single-use bioreactors market include Sartorius AG, Thermo Fisher Scientific, Danaher Corporation, and Merck Millipore. These companies spearhead innovation and provide advanced solutions in the realm of single-use bioreactors.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=44374840

Overall, the single-use bioreactors market is poised for significant growth, driven by the adoption of these cutting-edge bioreactors by startups and SMEs, their advantages over traditional counterparts, the expanding biologics and biosimilars market, and the continuous march of technological advancements. The dominance of the monoclonal antibodies segment, the rapid growth of mammalian cells, and the promising prospects in the Asia Pacific region further contribute to the market's optimistic outlook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Article source: https://article-realm.com/article/Business/45520-Single-Use-Bioreactors-Reshaping-Bio-pharmaceutical-Manufacturing-USD-10-0-Billion-by-2028.html